USD Speech, Language and Hearing Clinic Now Offers FDA Approved Tinnitus Treatment Device Lenire®
Neuromod Devices, the medical technology company that developed Lenire®, partnered with the USD Speech, Language and Hearing Clinic to address the growing demand for tinnitus treatment.
The USD Speech, Language and Hearing Clinic has been certified to administer Lenire®, following an intensive training program. Clinics for Lenire’s® latest expansion were selected based on their extensive experience treating tinnitus patients and ongoing commitment to tinnitus treatment innovation.
Lindsey Jorgensen, Ph.D., chair and professor in the Department of Communication Sciences & Disorders, says that evidence based Lenire® is a “fantastic opportunity for patients to get relief from tinnitus.”
“Our patients need an option for tinnitus treatment that has published studies and truly help patients who suffer from tinnitus,” she continued. “We are so happy to be providing this option for our area. We are proud to be providing this technology along with the other options. We continue to provide audiology and cochlear implant services to adults and children across the region. We also provide speech and language services to patients of all ages.”
Tinnitus, commonly known as “ringing in the ears,” is a complex brain signaling condition that causes people to perceive sound with no external source, affecting daily life. It is estimated that at least 25 million Americans are currently living with tinnitus. Tinnitus is also the most prevalent service-connected disability compensated for by the United States Veterans Administration (VA), with more than 2.9 million veterans compensated in 2023.
Neuromod aims to change this by working with leading tinnitus care experts, such as USD, in the U.S. and beyond.
"Neuromod’s mission is to create a new standard of care for tinnitus patients, and this goal is achievable only through collaboration with leading hearing and tinnitus care professionals,” said Eric Timm, Neuromod USA CEO and Neuromod Devices president of global commercial operations. “We are proud to expand Lenire’s® accessibility by establishing partnerships with professionals who share Neuromod’s uncompromising patient-centric approach to tinnitus care.”
Lenire® is a bimodal neuromodulation device that works by delivering mild electrical pulses to the tongue, through an intra-oral component called the Tonguetip®, combined with auditory stimulation through headphones to drive long-term changes in the brain to treat tinnitus. This dual action stimulus is proven to provide effective relief from tinnitus.
The USD Speech, Language and Hearing Clinic is now taking Lenire® assessment appointments. Tinnitus patients can learn more about tinnitus and book a Lenire® assessment by calling 605-658-3870.
About the USD Speech, Language and Hearing Clinic
USD’s Speech, Language and Hearing Clinic has been part of the USD accredited speech-language pathology and audiology program for over 50 years. The clinic provides evaluation, treatment and consultation services for children and adults with speech, language, hearing and related communication needs.
Learn more about the USD Speech, Language and Hearing Clinic.
About Neuromod Devices
Founded in 2010, Neuromod Devices is a global medical technology company with offices in Ireland and the U.S. Neuromod specializes in the design and development of neuromodulation technologies to address the clinical needs of underserved patient populations who live with chronic and debilitating conditions.
The lead application of Neuromod’s technology is in the field of tinnitus, where Neuromod has completed extensive clinical trials to confirm the efficacy of its non-invasive neuromodulation platform in this common disorder.
For more information visit www.neuromoddevices.com.
About Lenire®
Lenire® is the first non-invasive bimodal neuromodulation tinnitus treatment device shown to soothe and relieve tinnitus in large-scale clinical trials.
Lenire® has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified health care professional in Europe and has received a De Novo Approval Grant by the U.S. FDA.
Further details about Lenire® including a list of providers can be found at www.lenire.com.
You May Also Like
USD Introduces the 30 Under 30 Class of 2024
The University of South Dakota Alumni Association recently announced the 2024 class of 30 Under 30 recipients.
USD Libraries Celebrate One-Year Anniversary of Partnership with the Civil War & Reconstruction Governors of Mississippi Project
Funded by the National Historical Publications and Records Commission (NHPRC) and the National Endowment for the Humanities (NEH), CWRGM is an ambitious undertaking that provides insights into the diverse experiences of Americans during one of the most transformative periods in the nation’s history.
Association of American Law Schools names USD Professor and Law Student to Pro Bono Honor Roll
Knudson School of Law Professor Thomas Simmons and third-year law student Cameron Morgan were recognized for their service by the Section on Pro Bono Access to Justice.
